RARA and acute myeloid leukemia: Another study found that AML fueled by repressive transcription factors, such as PML‐RARα fusion oncoproteins (resulting from PML‐RARA) and AML1‐ETO (resulting from the fusion oncogene RUNX1‐RUNX1T1) display high sensitivity to inhibition of PARP.